{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-24-000036","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2024-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.001522+00:00","generated_at":"2026-05-31T02:45:53.809203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"iBio FY2024 net loss $24.9M; revenue $0.2M; auditor raises going concern","bullets":["Net loss narrowed to $24.9M from $65M YoY; R&D expense fell $5.1M, G&A fell $7.3M.","Cash, equivalents, restricted cash $14.4M at June 30, 2024; going concern warning in audit opinion.","Sold Texas manufacturing facility to Texas A&M for $8.5M, eliminating $13.2M secured debt.","Sold PD-1 asset to Otsuka for $1M upfront plus up to $52.5M milestones; entered AstralBio collaboration.","Raised ~$24M in equity (public offer $4.5M, PIPE $15M, warrant exercise $4.5M) after 1:20 reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-24-000036","json":"https://secwatch.observer/filing/0001420720-24-000036.json","markdown":"https://secwatch.observer/filing/0001420720-24-000036.md","text":"https://secwatch.observer/filing/0001420720-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000036/0001420720-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000036/ibio-20240630x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:45:53.809203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}